

Haematologica
HAEMATOL/2020/259952
Version 3

Acute leucoencephalomyelopathy and quadriparesis after CAR T-cell
therapy

Ranjit Nair, Gaëlle Drillet, Faustine Lhomme, Anthony Le Bras, Laure
Michel, John Rossi, Marika Sherman, Allen Xue, Anne Kerber,
Nutchawan Jittapiromsak, Linda Chi, Sudhakar Tummala, Sattva S.
Neelapu, and Roch Houot

Disclosures: LM received honoraria from Merck, Novartis, Roche, Biogen and Teva. JR, MS, AX, and AK are employees and stock holders of Gilead Sciences Inc. SSN reports research support from Kite/Gilead, Merck, Bristol-Myers Squibb, Cellectis, Poseida, Karus, Acerta, and Unum Therapeutics. He also serves as an advisory Board Member / Consultant for Kite/Gilead, Merck, Celgene, Bristol-Myers Squibb, Novartis, Unum Therapeutics, Pfizer, Precision Biosciences, Cell Medica, Allogene, Incyte, and Legend Biotech. RH received honoraria from Bristol-Myers Squibb, MSD, Gilead, Kite, Roche, Novartis, Janssen, and Celgene. NR, GD, FL, ALB, NJ, LC and ST report no conflict of interest.

Contributions: RH and SSN designed research, analyzed data, and wrote the paper. NR, GD, FL, ALB, LM, JR, MS, AX, AK, NJ, LC, ST performed research, analyzed data, and wrote the paper.